Mikel Portu

MD, Oncology.

[Mikel Portu @MGrive92]

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.
https://t.co/BrZfgj6MpP

[Oncobites.tv @OncobitesTv]

🎙️ #ASCO26 | ¡Nueva Entrevista Flash! Datos de vida real en cáncer de pulmón microcítico (SCLC) 🫁

El Dr. Yago Garitaonaindia @YGaritaonaindia entrevista en directo al Dr. Mikel Portu @MGrive92 para desgranar los resultados de un importante estudio con sello nacional:

📊 El estudio: Un análisis retrospectivo español que evalúa la supervivencia y los patrones de tratamiento en pacientes con carcinoma pulmonar de célula pequeña en el contexto de la práctica clínica real.
💡 El valor: Datos esenciales de "real-world evidence" (RWE) que complementan los resultados de los ensayos clínicos pivotales y reflejan el día a día de nuestros hospitales.

🎬 No te pierdas esta rápida conversación con las conclusiones clave en el vídeo completo👇
🔗 https://t.co/rHg7Lk8hy2

#Oncología #CáncerDePulmón #SCLC #RealWorldEvidence #RWE #InvestigaciónClínica #ASCO2026 #OncoBites

[OncoSantPau @OncoSantPau]

El Dr.Portu i l’equip de pulmó presenten a #ASCO26 un pòster sobre factors pronòstics i eficàcia del tractament de 1a linia de #CPCP amb quimio-immunoteràpia.
#orgullsantpau @HospitalSantPau

[Mikel Portu @MGrive92]

@OncoSantPau @HospitalSantPau @IRSantPau 👏🏻

[OncoSantPau @OncoSantPau]

El Dr.Portu ha publicat una revisió de carcinomes renals amb reordenament de TFE3 o alteracions TFEB.
Enhorabona! #orgullsantpau @HospitalSantPau @IRSantPau

[Mikel Portu @MGrive92]

Happy to share our comprehensive review on MiT-RCC — now published in @Cancers_MDPI!

🔗 https://t.co/bVcSXt8woW

TFE3/TFEB-driven kidney cancers are rare but increasingly treatable. We review the molecular biology, modern diagnostics, and emerging evidence for ICI + VEGFR-TKI combinations in metastatic tRCC.

Key takeaway: fusion partner identity shapes both prognosis and treatment response. Precision matters.

Thanks to the whole team — @MarioBalsaMD @OncoSantPau @ICO_oncologia

@myESMO @_SEOM @OncoAlert @Uromigos @IKCCorg @RenalCancerNews

[Mario Balsa @MarioBalsaMD]

Our new review is out! 📚 @Cancers_MDPI

🔗 https://t.co/rJkFMzkmJg

🤔 TFE3-rearranged and TFEB-altered renal cell carcinomas remain among the most fascinating (and challenging) entities within MiT family RCCs

In this review we dissect:
🧬 Molecular landscape of MiT-RCC
🎯 Key diagnostic tools (GPNMB IHC, TRIM63 RNA ISH…)
💥 Emerging evidence for ICI + VEGFR-TKI combinations in M1 disease

In MiT-RCC, when TFE3/TFEB rearrange the genome…they also rearrange the way we think about kidney cancer 💡

Thank you to my friend @MGrive92 and to all the team from @OncoSantPau & @ICO_oncologia!

@OncoAlert @OncoReporte @myESMO @_SEOM @Uromigos @IKCCorg @RenalCancerNews

[Mikel Portu @MGrive92]

@MarioBalsaMD @Cancers_MDPI @OncoSantPau

[Mikel Portu @MGrive92]

Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy? https://t.co/MhVZoD8J0S

[European Association of Urology (EAU) @Uroweb]

🏆 #EMUC25 Best Abstract Award - M.I. Galante Romo, Madrid (ES)
For the paper: "Real world evidence of adjuvant pembrolizumab in renal cell carcinoma (RCC) from a Spanish registry: The ARENAL trial from the GUARD consortium."

[ETOP IBCSG Partners Foundation @etop_ibcsg]

Soon finishing day 2 of our 14th ETOP Residential Workshop with great presentations from the faculty, very interesting project proposals from our participants and lively discussions.

[Mikel Portu @MGrive92]

First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)) - Clinical Lung Cancer https://t.co/bR2oxSe2rq

[Mikel Portu @MGrive92]

Molecular Determinants of Survival in Metastatic Uveal Melanoma: The I... https://t.co/ZphwQx6Rin

[Judit Sanz Beltran @juditsanz]

Magnífica presentació de “First line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study” per @margamajem @OncoSantPau @myESMO #ELCC25

[Mikel Portu @MGrive92]

@twobitidiot Why do you lie so blatantly?

[OncoSantPau @OncoSantPau]

💜 Cursa anual benèfica per la investigació en Càncer Renal ‼️#els10dlf
🏃‍♂️🏃🏃‍♀️ 10km
📅 Diumenge 17 de Novembre
🕙 10h
Inscripcions: https://t.co/ztsJm94iIn
@HospitalSantPau @IRSantPau @Maroto5Pablo @GeorgiaAnpa @MGrive92

[Ash Paul @pash22]

THEOREMM: A Novel Framework for Cancer Registration Trials.
"Trials in HEmatology and Oncology REviewed by Metaresearch Methods" https://t.co/yfnrg2tpRR via @VPrasadMDMPH & @Timothee_MD

[Institut Català d'Oncologia @ICO_oncologia]

Avui hem fet l'acte de comiat dels i les residents de darrer any de l'@ICO_oncologia.
Enhorabona per haver finalitzat l'especialitat i molts èxits en aquesta nova etapa que ara comenceu!
De ben segur esteu preparats! 💪
#ICONICpeople #residents

[Mikel Portu @MGrive92]

Great time at #GUARDSymposium2024

[MJosé Juan @mjuanfi81]

If you are starting in the genitourinary world,if you need to convey your ideas,if you want us to help you dive in,here you have the QR.Sign up and we will contact you.The YOUNG GROUP is already up and running
@T_AlonsoGordoa @JaviMolinaC @Uro_Oncologist @elenasefer @Dav_Lorente

[Tom Powles @tompowles1]

Bladder surgery sparing approaches will superceed cystectomy according to @AndreaNecchi . #GUARDSymposium2024